文献速递前列腺增生与排尿功能障碍

当代良性前列腺增生手术治疗方案的成本效益比较

Cost-Effectiveness of Contemporary Surgical Treatment Options for Benign Prostatic Hyperplasia.
PubMed 文献 · Urology · 2026-08-26

本研究采用微观模拟模型,按前列腺体积分层比较所有指南支持的BPH手术方案的成本效益。结果显示,对于30-80cc和80-150cc前列腺,HoLEP均最具成本效益,但成本效益高度依赖患者对术后射精功能障碍和排尿症状改善的重视程度。

要点

  • 对于30-80cc前列腺,HoLEP的QALY最高(12.25),ICER低至6931美元/QALY。
  • 对于80-150cc前列腺,HoLEP成本(8361美元)显著低于SP(19012美元)和RWT(11969美元)。
  • 成本效益结论高度依赖患者对术后射精功能和症状改善的个体偏好。

核心结论

  • 在人群水平假设下,HoLEP是平均或大体积前列腺BPH患者最具成本效益的手术选择。
  • 成本效益高度依赖患者对术后射精功能障碍和排尿症状改善的重视程度,强调基于个体偏好的手术选择。

研究设计与样本

  • 采用微观模拟模型进行成本效益分析,比较所有指南支持的BPH手术方案,按前列腺体积分层。
  • 模型概率基于已发表数值,效果采用术后结局计算,成本从美国Medicare支付方角度,使用QALY和ICER评估成本效益。

主要发现

  • 对于30-80cc前列腺,HoLEP的QALY最高(12.25),其次为iTIND(12.02)和WVTT(11.98)。
  • BPH每患者成本从6557美元(WVTT)和8431美元(HoLEP)到16230美元(PAE)不等,HoLEP的ICER较低(6931美元/QALY)。
  • 对于80-150cc前列腺,HoLEP的效果与SP几乎相同(12.25 vs 12.26 QALYs),且优于RWT(12.19 QALYs)。
  • HoLEP成本(8361美元)显著低于SP(19012美元)、RWT(11969美元)和PAE(16230美元),因此具有成本效益。

临床怎么用

  • 对于平均或大体积前列腺的BPH患者,HoLEP可作为具有成本效益的手术选择。
  • 手术决策应结合患者对术后射精功能和症状改善的个体偏好进行选择。

局限性

  • 成本效益结果依赖于模型假设和已发表的概率值。
  • 成本效益结论受患者对术后射精功能障碍和症状改善的价值观影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the cost-effectiveness of all guideline-supported surgical management options for BPH, stratified by prostate size. METHODS: Using a microsimulation model, a cost-effectiveness analysis was performed comparing all guideline-supported surgical management options for BPH, stratified by prostate size. Model probabilities were based on published values and effectiveness was calculated using post-operative outcomes. Costs were from a US Medicare payer perspective, with quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) used to assess cost-effectiveness. RESULTS: At a lifetime horizon for patients with 30-80cc prostate size, HoLEP resulted in the highest QALYs (12.25), followed by iTIND (12.02) and WVTT (11.98). BPH costs per patient ranged from $6557 (WVTT) and $8431 (HoLEP) to $16,230 (PAE), with a low ICER for HoLEP ($6931/QALY). For large glands (80-150cc), HoLEP resulted in nearly identical effectiveness relative to SP (12.25 vs 12.26 QALYs) and more than RWT (12.19 QALYs). HoLEP had a significantly lower cost ($8361) than SP ($19,012), RWT ($11,969), and PAE ($16,230) and was therefore cost-effective. However, for both index patients, cost-effectiveness was dependent on the value placed on post-operative ejaculatory dysfunction and post-surgery urinary symptom improvement. CONCLUSION: At base-case with population-level assumptions, HoLEP is the most cost-effective BPH surgical option for patients with average or large prostate size. However, this is highly dependent upon patient priorities, highlighting the importance of surgical selection driven by individual patient preferences.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Wymer KM, Lehner K, Sharma V, et al. Cost-Effectiveness of Contemporary Surgical Treatment Options for Benign Prostatic Hyperplasia. Urology. 2026. PMID: 42648558. doi:10.1016/j.urology.2026.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。